Donor-derived cell-free DNA predicts allograft failure and mortality after lung transplantation
MetadataShow full item record
AbstractBackground: Allograft failure is common in lung-transplant recipients and leads to poor outcomes including early death. No reliable clinical tools exist to identify patients at high risk for allograft failure. This study tested the use of donor-derived cell-free DNA (%ddcfDNA) as a sensitive marker of early graft injury to predict impending allograft failure. Methods: This multicenter, prospective cohort study enrolled 106 subjects who underwent lung transplantation and monitored them after transplantation for the development of allograft failure (defined as severe chronic lung allograft dysfunction [CLAD], retransplantation, and/or death from respiratory failure). Plasma samples were collected serially in the first three months following transplantation and assayed for %ddcfDNA by shotgun sequencing. We computed the average levels of ddcfDNA over three months for each patient (avddDNA) and determined its relationship to allograft failure using Cox-regression analysis. Findings: avddDNA was highly variable among subjects: median values were 3.6%, 1.6% and 0.7% for the upper, middle, and low tertiles, respectively (range 0.1%-9.9%). Compared to subjects in the low and middle tertiles, those with avddDNA in the upper tertile had a 6.6-fold higher risk of developing allograft failure (95% confidence interval 1.6-19.9, p = 0.007), lower peak FEV1 values, and more frequent %ddcfDNA elevations that were not clinically detectable. Interpretation: Lung transplant patients with early unresolving allograft injury measured via %ddcfDNA are at risk of subsequent allograft injury, which is often clinically silent, and progresses to allograft failure. Fund: National Institutes of Health. © 2019
SponsorsThe Genome Transplant Dynamics Study ( NCT01985412 ) is funded by the National Institutes of Health , Grant RC4AI092673 . The Genomic Research Alliance for Transplantation Study ( NCT02423070 ) is funded by the Division of Intramural Research of the National Heart, Lung, and Blood Institute . Funders had no role in study design, data collection, data analysis, interpretation, writing of the report.
donor-derived cell-free DNA
Identifier to cite or link to this itemhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85060510387&doi=10.1016%2fj.ebiom.2018.12.029&partnerID=40&md5=ade58930f69b7b6f7e2130d51198fb03; http://hdl.handle.net/10713/8725
- Late manifestation of alloantibody-associated injury and clinical pulmonary antibody-mediated rejection: Evidence from cell-free DNA analysis.
- Authors: Agbor-Enoh S, Jackson AM, Tunc I, Berry GJ, Cochrane A, Grimm D, Davis A, Shah P, Brown AW, Wang Y, Timofte I, Shah P, Gorham S, Wylie J, Goodwin N, Jang MK, Marishta A, Bhatti K, Fideli U, Yang Y, Luikart H, Cao Z, Pirooznia M, Zhu J, Marboe C, Iacono A, Nathan SD, Orens J, Valantine HA, Khush K
- Issue date: 2018 Jul
- Use of donor-derived-cell-free DNA as a marker of early allograft injury in primary graft dysfunction (PGD) to predict the risk of chronic lung allograft dysfunction (CLAD).
- Authors: Keller M, Bush E, Diamond JM, Shah P, Matthew J, Brown AW, Sun J, Timofte I, Kong H, Tunc I, Luikart H, Iacono A, Nathan SD, Khush KK, Orens J, Jang M, Agbor-Enoh S
- Issue date: 2021 Jun
- De Novo DQ Donor-Specific Antibodies Are Associated with Chronic Lung Allograft Dysfunction after Lung Transplantation.
- Authors: Tikkanen JM, Singer LG, Kim SJ, Li Y, Binnie M, Chaparro C, Chow CW, Martinu T, Azad S, Keshavjee S, Tinckam K
- Issue date: 2016 Sep 1
- Applying rigor and reproducibility standards to assay donor-derived cell-free DNA as a non-invasive method for detection of acute rejection and graft injury after heart transplantation.
- Authors: Agbor-Enoh S, Tunc I, De Vlaminck I, Fideli U, Davis A, Cuttin K, Bhatti K, Marishta A, Solomon MA, Jackson A, Graninger G, Harper B, Luikart H, Wylie J, Wang X, Berry G, Marboe C, Khush K, Zhu J, Valantine H
- Issue date: 2017 Sep
- Erratic tacrolimus exposure, assessed using the standard deviation of trough blood levels, predicts chronic lung allograft dysfunction and survival.
- Authors: Gallagher HM, Sarwar G, Tse T, Sladden TM, Hii E, Yerkovich ST, Hopkins PM, Chambers DC
- Issue date: 2015 Nov